Compass Therapeutics (CMPX) Gains Analyst Confidence with Promising Cancer Pipeline

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the top high-return penny stocks to buy now. On July 14, Stifel reiterated its Buy rating and $11.00 price target for CMPX. The firm views the extended timeline for topline data from the Phase 2/3 COMPANION-002 trial—now expected in Q4 2025—as a positive, given the 19-month follow-up in a cancer type with typically short survival rates.

A research team in lab coats testing a new ImmunoPhage platform in a modern biotechnology lab.

Beyond COMPANION-002, Stifel highlighted two upcoming 2025 catalysts: Phase 1 results for CTX-8371, a PD-1xPD-L1 bispecific antibody, and preclinical data on CTX-10726 targeting PD-1 and VEGF-A. Interest is also growing around CTX-837’s unique multi-modal mechanism, reinforcing Compass’s innovation in immuno-oncology.

Compass Therapeutics, Inc. (NASDAQ:CMPX) is a clinical-stage biotech company developing antibody-based cancer treatments in the U.S. Its lead candidates include bispecific antibodies like tovecimig (targeting DLL4 and VEGF-A), CTX-471 (stimulating CD137 for immune activation), and CTX-8371 (blocking PD-1/PD-L1). The company also advances CTX-10726 and VEGF-focused bispecifics aimed at enhancing anti-tumor immunity and inhibiting angiogenesis.

READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts.

Disclosure: None. This article is originally published at Insider Monkey.